

Using various techniques to identify antimicrobial susceptibility and phenotypic resistance in a *Shigella*'s spp.

Saja Salim Abdulhassan

*Department of Biology, College of Science, University of Babylon, Iraq,
sajaalkaraawi@gmail.com*

Hassan Fadhil Naji

Department of Biology, College of Science, University of Babylon, Iraq.

Abstract

Shigellosis should be suspected in patients who have a fever and watery diarrhea. Females were found to be infected at a higher rate than males in the overall population samples. The rate of bacterial isolation (17%) was higher than his results (3%), with approximately 53.5% of children infected, approximately 24% in the 11-20 age range, and approximately 22.5% in the early teens and adults (21-30 years). People at nursing homes and psychiatric institutions who had various gastrointestinal symptoms were cured.

Shigella spp. were all resistant (43.6%) to ampicillin plus nalidixic acid (=60%), cefixicin (59.5%), ceftazidime (55%), and ceftriaxone (55%). When antibiotic susceptibility was investigated, *Shigella* spp. isolates were 76.6% susceptible to ciprofloxacin and 44% susceptible to ceftriaxone, respectively. Almost 100% of the samples tested were insensitive to AMP, 45% to NAL, 55% to ceftriaxone, 15% to CIP, 60% to CHL and cefixime, 65% to ceftazidime, and 40% to gentamicin. *S. flexneri* isolates were resistant to ampicillin and erythromycin in 100% of cases, while 66.66% were responsive to eftriaxone, ciprofloxacin, gentamicin, and 33.33% were resistant to ceftriaxone, ciprofloxacin, and nalidixic acid. In the case of *S. Sonnei*, 100% of isolates were resistant to ampicillin and cefixime, while 100% were intermediate to gentamicin and 75.00% were sensitive.

Keywords: *Shigella* spp., Antibiotic sensitivity, phenotypic test.

INTRODUCTION

Shigella is a gastrointestinal bacterium that is highly infectious and sometimes fatal. DuPont et al. (1989) discovered that consuming 10-100 *Shigella* dysentery can cause illness in healthy persons. *Shigella*'s endotoxin, exotoxin, enterotoxin, and temperature regulation genes can cause fever, bloody, purulent feces, and stomach cramps. Hemolytic uremic syndrome, hypoglycemia, hypoxemia, intestinal perforation, convulsions, dementia, and even death can occur in some people. Some patients, on the other hand, may only experience short-term

illness. According to the WHO in 1999, dysentery affects 165 million people worldwide each year, with about 162 million of those people residing in underdeveloped countries. Dysentery was the cause of mortality for 1.1 million people, the majority of whom were children under the age of five (Navia et al.,1999). *Shigella* spp.

Shigella spp. are Gram-negative bacteria that are rod-shaped, nonspore-forming, facultative anaerobes, and nonflagellated. They induce acute diarrhea, which can proceed to bloody excess mucus diarrhea, a condition known as bacillary dysentery (or

shigellosis) (AL-Musawi et al., 2016 ; Kahsay and Muthupandian, 2016). *Shigella* was identified as a life-threatening bacteria by the WHO in 1996 due to increasing treatment resistance, morbidity connected to socioeconomic variables, public health issues, lifestyle choices, and epidemic *Shigella* serotypes. Bacterial dysentery must be controlled by eliminating the source of infection, restricting the transmission vector, and safeguarding vulnerable people as soon as possible. *Shigella* has recently become more resistant to medicines, making treatment less effective. *Shigella* patients that have a long illness course are a major source of infection for others, posing considerable clinical issues (Yan et al., 2010).

Materials and Procedures:

Sample assembly:

Two hundred samples of stool were gathered from people of all ages (adults, adolescents, and children), including both men and women. Between November 2020 and May 2021, stool samples were collected from patients with diarrhea who were admitted to general hospitals, teaching hospitals for women and children, and Al-Diwaniyah teaching hospitals.

Identification and isolation:

The specimens were grown on blood agar (Himedia) in a sterile loop for 24 hours at 37 C°. At 4 C°, pure colonies were kept in nutritional broth containing glycerol (Himedia). Bacteria cultured on MacConkey agar, blood agar, and nutrient agar (Himedia) were investigated for their form, size, texture, and colony organization. A single colony of each isolate was Gram stained and inspected under a 100x oil-emersion light microscope; the isolates were identified using morphological qualities (for cells and colonies) and biochemical tests as reported by MacFaddin (2000), as well as the polymerase chain reaction approach.

Result and discussion:

Demographic characteristics according to the gender and age

Out of 200 patients, only 20 (10.00%) were diagnosed as shigellosis (Table 1). The samples were divided into eighty-five (43%)-males and One hundred and fifteen (57%)-females. The age of patients was divided into three categories. Table .1 showed that the less than 11 years was 107 (53.5%), 11-20 years was 48 (24%), and 21-30 years was 45 (22.5%).

Table (1): Demographic characteristics (Total samples, positive and negative, gender and age).

Characteristic	Category	No. (%)	X ²	P-value
Gender	Male	85(42.5)	9*	0.003
	female	115(57.5)		
	Total	200(100)		
Age	Less than 11	107(53.5)	55.005*	0
	11-20	48(24)		
	21-30	45(22.5)		
	total	200(100)		
Total	Positive	20(10%)	8.5*	0.002
	Negative	180(90%)		
	Total Samples	200(100%)		

However, females were infected at a higher rate than males in the total population samples. Age groups were further divided into

three subgroups ranging from 4 to 30 years, with approximately 53.5% of children infected, approximately 24% in the 11-20 age

group, and approximately 22.5% in the early teens and adults (21–30 years). In contrast to *S. flexneri* serotype variant X (prevalent in urban areas), which equally affects men and women, Jain et al. (2020) discovered that *S. flexneri* serotype 2 affected women much more than males (predominantly in rural areas). Males were more resistant to disease, and antimicrobial treatments were more successful because men's metabolic systems were biologically faster and more potent than women's. *Shigella* spp. persisted in the body for longer than usual due to women's more sensitive temperaments, making them less resistant (Ranjbar and Farahani, 2019). Since children's guts are still developing, they receive low dosages of antibiotics to avoid acquiring resistance to the bacteria, which is beneficial to their gut health.

Additionally, broad-spectrum antibiotics eliminate a large number of important intestinal microbes. Similar trends were discovered in adolescents, although they are more likely to be explained by changes in food intake and sanitation than by heredity (Ngoshe et al., 2017). The typical method for examining the cause of dysentery involves doing precise bio-chemical checks to determine the type and class of bacteria through culture, characterized by a tedious and long time. For the detection of shigellosis, DNA-dependent molecular approaches, particularly the PCR method, are now often utilized in scientific and research facilities (Alipour et al., 2012).

Demographic characteristics according to the symptoms:

There were big differences among patients according to the symptoms (diarrhoea conditions) using X² test. The percentage of the patients with shigellosis were shown in Table (2); all patients suffering from abdominal pain (100 %, 20 / 20), fever (51 %, 102 / 200), vomiting (69 %, 138 / 200),

nausea (47 %, 94 / 200) and fatigue (16 %, 32 / 200).

Table (2): Distribution of specimens according to patients' clinical signs.

Signs	Patient No.	percentage (%)
Abdominal pain	200	100
Fever	102	51
Vomiting	138	69
Nausea	94	47
Fatigue	32	16
X ²	310.14*	
P-value	0	

* Significant difference at $p \leq 0.05$

The percentage of the patients with shigellosis were as shown in table (3); patients suffering from mucoid bloody (50 %, 10 / 20), soft bloody (20 %, 4 / 20), liquid bloody (20 %, 4 / 20), and liquid mucoid (10 %, 2 / 20).

Table (3): Distribution of specimens according to patient's diarrhoea conditions.

Signs	Patient No.	(%)
Mucoid bloody	10	50
Soft bloody	4	20
Liquid bloody	4	20
Liquid mucoid	2	10
X ²	18.33*	
P-value	0	

* Significant difference at $p \leq 0.05$

The clinical symptoms are indications of various serotypes of *Shigella* species, which are different in every age group and gender due to the bacterial load and resistivity and how the defense mechanism behaves and counter-attacks the several kinds of species present inside the body during the onset of infection (Maharjan et al., 2017). Ibraheem, (2016) conducted a local investigation in Baghdad that found *Shigella* spp. to be the next (12%) prevalent bacterium isolated from Ninety- two pediatric cases with diarrhoea. In comparison to the study of Ashkenazi et al. (2003), the rate of bacterial isolation (17%)

was higher than his results (3%). Patients with various symptoms of diarrhea who are lying in nursing homes and psychiatric institutions have been cured (Sheikh et al., 2019). Additionally, homosexual males are more likely to have *S. flexneri* infections, and persistent, relapsing sickness has been shown to make HIV infection more difficult (Anandan et al., 2017). Shigellosis should be suspected in patients who have fever and watery diarrhea. Clinically, it is impossible to differentiate between diarrhea and a bacterial, viral, or protozoan infection. Infections with enterotoxigenic *E. coli* and non-typhoidal *Salmonella* frequently result in nephrotic syndrome and vomiting (Sati et al., 2019). Bloody or mucoid stools, on the other hand, may indicate *S. enteritidis*, *Yersinia enterocolitica*, *Campylobacter* species, or *Entamoeba histolytica*, all of which should be included in the differential diagnosis. Patients with amebiasis have blood in their stools, albeit it is usually dark brown rather than bright red, as with *Shigella* infections. Microscopically, amebiasis stool smears should show erythrophagocytic trophozoites in the absence of polymorphonuclear leukocytes (PMNs), but bacillary dysentery stool smears should show sheets of PMN (Halimeh et al., 2020). On sigmoidoscopic examination, patients with shigellosis have a diffusely erythematous mucosal surface with tiny ulcers, whereas those with amebiasis have distinct ulcers without generalized inflammation (Ahmed et al., 2021).

Depending on the *Shigella* serotype that causes infection, the amount of infection, the host's age, and immunity, the clinical symptoms of *Shigella* infection might range from mild diarrhea to severe dysentery (Lampel and Maurelli, 2007). Fever, tiredness, and watery diarrhea are early symptoms. In more severe forms of dysentery, patients may have abdominal pain, nausea, and vomiting as well as recurring, unpleasant stools that

contain blood and mucus (Niyogi, 2005; Nygren et al., 2013).

Identification of *Shigella* isolates on different media:

Shigella are small, rod-shaped organisms. About 20 *Shigella* isolates were identified from the total samples. As shown in figure (1), when *Shigella* isolates were cultured colonies of non-lactose fermenters that are transparent and pale developed on MacConkey agar. *Salmonella-Shigella* agar performed worse than Hekton enteric and xylose-lysine-desoxycholate agar, and required more work to do so (Pollock and Dahlgren, 1974). Samples must be plated on MacConkey with one of the following agars: xylose-lysine-desoxycholate, Hektoen enteric, or deoxycholate citrate in order to best detect *Shigella* in feces.

Shigella does not create H₂S, hence its colonies on Hektoen agar were bluish-green rather than the salmon-colored *Salmonella* colonies' black centers. *Shigella* is not a lactose or xylose fermenter and exhibits a high level of biochemical inertness (Dekker and Frank, 2015). *Shigella* most commonly does not create gas, with the exception of some *S. flexneri* strains, which are outliers and may ferment lactose (Nataro et al., 2007). Kligler iron or triple sugar iron agar were used to further describe the appropriate colonies. *Shigella* lysine decarboxylase tests usually come out negative. The biochemical properties of Groups A, B, and C are comparable, although *S. sonnei* has ornithine decarboxylase activity and beta-galactosidase activity, according to Koneman et al. (1997).

Identification of *Shigella* isolates using biochemical test

The results of the current study of the chemical tests (Indole, catalase and oxidase) showed that all isolates of *Shigella* were positive for Indole and Catalase. As for the

negative, it was for examining the oxidases in the types identified in table (4).

Table (4): Biochemical tests conducted on the isolated pathogenic bacteria (n=20).

<i>Shigella</i> species	Indole	Catalase	Oxidase
<i>S. flexneri</i>	+	+	-
<i>S. Sonnei</i>	+	+	-
<i>S. dysenteriae</i>	+	+	-
<i>S. boydii</i>	+	+	-

This result is in line with the Bergey's Manual of Determinative Bacteriology (Holt et al., 2012). Regarding the negative biochemical tests, they included urease, lysine decarboxylase, ornithine decarboxylase, and some isolates produce a red ring as a positive result in the indole assay (Saima et al., 2018; Abady et al., 2019). Other study found that *Shigella* spp. have positive result in Methyl Red, Voges Proskauer, Indole, and Triple Sugar Iron (Chhanda et al., 2019).

Antimicrobial susceptibility test :

Shigella species differed in the presence of resistance genes, and there were statistically significant differences among them as shown

in (Table 5). The bacteria were highly resistant to ampicillin and nalidixic acid (=60%), cefixime (59.5%), ceftazidime (55%), and ceftriaxone (55%), were all *Shigella* spp. Resistant (43.6 %). *Shigella* spp. isolates were 76.6 % susceptible to ciprofloxacin and 44 % susceptible to ceftriaxone, respectively, when susceptibility to antibiotics was examined. About 100 % of the samples examined were insensitive to AMP, 45% to NAL, 55% to ceftriaxone, CIP (15%), CHL and cefixime (60%), ceftazidime (65%), and gentamicin (40%).

Regarding to *S. flexneri* 100% of isolates were resistance to ampicillin and erythromycin, while 66.66% of isolates were sensitive to ceftriaxone, ciprofloxacin, gentamicin and 33.33% of isolates were resistance to ceftriaxone, ciprofloxacin and nalidixic acid as shown in (Table 6). Regarding to *S. Sonnei* 100% of isolates were resistance to ampicillin, and cefixime, while 100% of isolates were intermediate to gentamicin and 75.00 % of isolates were sensitive to ceftriaxone as shown in (Table 7).

Table (5): Antimicrobial susceptibility test (number and percentage).

Antibiotic	Sensitive isolates		Intermediate isolates		Resistance isolates	
	<i>N</i>	%	<i>N</i>	%	<i>n</i>	%
Ampicillin	0	0	0	0	20	100
Ceftriaxone	6	30	3	15	11	55
Erythromycin	0	0	2	10	18	90
Chloramphenicol	4	20	4	20	12	60
Ceftazidime	3	15	4	20	13	65
Ciprofloxacin	12	60	5	25	3	15
Gentamicin	3	15	9	45	8	40
Cefixime	5	25	3	15	12	60
Nalidixic acid	2	10	9	45	9	45
<i>X²</i>	61.72*					
<i>P-value</i>	0					

Regarding to *S. sonnei* 100% of isolates were resistance to ampicillin, 69.23 % of isolates were resistance to ceftriaxone and ceftazidime

while 53.85% of isolates were sensitive to ciprofloxacin as shown in (Table 8).

Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method, as recommended by the clinical and Laboratory Standards Institute (CLSI, 2022). All isolates were tested for antibiotic susceptibility using ceftriaxone (30

g), ampicillin (10 g), chloramphenicol (30 g), nalidixic acid (30 g), trimethoprim-sulfamethoxazole (SXT, 25 g), ceftazidime (30 g), ciprofloxacin (5 g), cefixime (5 g), and gentamicin (10 g) as (Mast Diagnostics Ltd., Merseyside, UK) (Ali et al., 2020).

Table 6: Antimicrobial susceptibility test (number and Percentage) of *S. flexneri*.

Antibiotic agent	Sensitive isolates		Intermediate isolates		Resistance isolates	
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%
Ampicillin	0	0.00	0	0.00	3	100
Ceftriaxone	2	66.66	0	00.00	1	33.33
Erythromycin	0	0	0	00.00	3	100
Chloramphenicol	0	00.00	3	100	0	0
Ceftazidime	0	00.00	0	00.00	2	66.66
Ciprofloxacin	2	66.66	0	00.00	1	33.33
Gentamicin	2	66.66	0	00.00	1	33.33
Cefixime	0	00.00	1	33.33	2	66.66
Nalidixic acid	0	00.00	2	66.66	1	33.33

Table (7): Antimicrobial susceptibility test (number and Percentage) of *S. Sonnei*.

Antibiotic	Sensitive isolates		Intermediate isolates		Resistance isolates	
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%
Ampicillin	0	0.00	0	0.00	4	100
Ceftriaxone	3	75.00	1	25.00	0	0
Erythromycin	0	00.00	1	25.00	3	75.00
Chloramphenicol	0	00.00	2	50.00	2	50.00
Ceftazidime	1	25.00	1	25.00	2	50.00
Ciprofloxacin	0	00.00	2	50.00	2	50.00
Gentamicin	0	00.00	4	100	0	00.00
Cefixime	0	00.00	0	00.00	4	100
Nalidixic acid	0	00.00	1	25.00	3	75.00

Table (8): Antimicrobial susceptibility test (number and Percentage) of *S. dysenteriae*.

Antibiotic	Sensitive isolates		Intermediate isolates		Resistance isolates	
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%
Ampicillin	0	0.00	0	0.00	13	100
Ceftriaxone	2	15.38	2	15.38	9	69.23
Erythromycin	0	0.00	1	7.69	12	92.31
Chloramphenicol	2	15.38	1	7.69	10	76.92
Ceftazidime	2	15.38	2	15.38	9	69.23
Ciprofloxacin	7	53.85	2	15.38	4	30.77

Gentamicin	1	7.69	4	30.77	8	61.54
Cefixime	5	38.46	2	15.38	6	46.15
Nalidixic acid	1	7.69	6	46.15	6	46.15

The susceptibility of *Shigella* to antibiotics varies according to dosage and formulation. Shigellosis is a disease that mostly affects children in areas of developing countries where it is endemic (Abdulhassan and Naji, 2022). However, Specialists advise the need to treat infected people to prevent transmission and control of infection (Ngoshe et al., 2017). Although *Shigella* species-related infectious diarrhoea is frequently self-limiting, as a result, empiric antibiotic therapy is frequently used in, as a result, antibiotic treatment is frequently used in children carrying symptoms before the result of stool culture. Most patients will notice an improvement in their symptoms even before the results are available (Alemu et al., 2019). Resistance to nalidixic acid, tetracycline, and trimethoprim-sulfamethoxazole exists in *S. sonnei* strains. Nalidixic acid-resistant bacteria displayed decreased susceptibility to fluoroquinolones but not complete resistance (Sheikh et al., 2019). In a drug susceptibility test, *S. dysenteriae* showed resistance to quinolone antibacterial drugs. Streptomycin and spectinomycin are two aminoglycoside antibiotics that bind to ribosomal subunits and limit protein synthesis at intracellular sites (Rahman and Sarker, 2021). A significant ratio of immovability to AMP, TM, and TAC was noted in numerous earlier investigations conducted in Iran and other nations (Jomezadeh et al., 2014). *Shigella* species and cefotaxime resistance were found to be significantly correlated ($p < 0.05$). *S. flexneri* strains were primarily resistant to quinolones and chloramphenicol, although overall study revealed that *S. sonnei* had stronger antibiotic resistance than other species. To ciprofloxacin, all *Shigella* isolates were sensitive (Sambe-Ba et al., 2013; Hosseini Nave et al., 2016). Ciprofloxacin is beneficial against shigellosis. Multi drug resistant (MDR) *Shigella*

developed due to the medication's overuse and abuse in the treatment of diarrhoea and urinary tract infections (Hussen et al., 2019). Another study from the University of Kolkata discovered that quinolones were 90% resistant to the antibiotics tested (Halimeh et al., 2020).

According to antibiotic susceptibility statistics, ciprofloxacin resistance increased from 57.1% to 100% over five years, while ampicillin resistance ranged between 35.70% and 81.250%. Additionally, nalidixic acid and cotrimoxazole were completely resistant to pressure (Pakbin et al., 2021). Sheikh et al. (2019) discovered identical resistance patterns in 2015-2016, with the same prevalence of indicated resistance (33.3%).

Antibiotic resistance changes as a result of plasmid-borne gene transfer. In their analysis, 43.7% of samples were insensitive to furazolidone, and 33.3% were insensitive to gentamicin (Sati et al., 2019). According to antibiotic susceptibility statistics, ciprofloxacin resistance increased from 57.1 to 100%, while ampicillin resistance ranged between 35.7% and 81.25%. Between 2014 and 2016, nalidixic acid and cotrimoxazole displayed 100% resistance (Anandan et al., 2017). Brander et al. (2017) discovered a similar level of resistant reluctance. About a quarter of the samples were resistant to one of the third generation cephalosporins. *S. sonnei* strains were 20% resistant to cefotaxime or ceftriaxone, whilst *S. flexneri* strains were 11.76% resistant. *Shigella* spp. resistance to cephalosporins was reported to be between 2% and 5.2% in Southeast Asian research (Chung et al., 2016).

According to a large multicenter study conducted in eight Asian nations (Drprabhurajeshwar et al., 2015), resistance to ceftriaxone increased by 5% in *Shigella* strains

between 2001 and 2004. As a referral center, they accept patients that have been treated partially or completely, which may show the accurate occurrence of *Shigella* spp. (Jain et al., 2020).

Conclusion:

According to antibiotic susceptibility statistics, Ciprofloxacin resistance increased from 57.1 to 100%, whilst ampicillin resistance ranged between 35.7% and 81.25%. *S. sonnei* isolates were 100% resistant to ampicillin, 69.23% resistant to ceftriaxone and ceftazidime, and 53.85% susceptible to ciprofloxacin.

Reference

Abady, N.R. ; C.J.D. Guglielmino, R.M. Graham, J. Adelskov, H.V. Smith, B.K.C. Patel, and A.V. Jennison. Genetic characterization of a *Neisseria meningitidis* cluster in Queensland, Australia. *Canadian Journal of Microbiology*. 63(7): 644-647. <https://doi.org/10.1139/cjm-2017-0017>

Abdulhassan , S.S and Naji, H.F. (2022). Role of Extended Spectrum B-lactamase Genes in Antibiotics Resistance of *Shigella* spp. *Azerbaijan Medical Journal*.62(9):4387

Ahmed D., Al-Ajeeli K., and Hasan A. (2021). Multiple and extended drug resistance of shigella species isolated from patients with gastroenteritis in Baghdad, Iraq. *Biochemical and Cellular Archives*. 21:2991–3001.

Alemu A., Geta M., Taye S., Eshetie S., and Engda T. (2019). Prevalence, associated risk factors and antimicrobial susceptibility patterns of *Shigella* infections among diarrheic pediatric population attending at Gondar town healthcare institutions, Northwest Ethiopia. *Tropical Diseases, Travel Medicine and Vaccines*. 5:7.

<https://doi.org/10.1186/s40794-019-0079-7>

Ali M., Diso S., Mu'azu L., Nas F., and Salihu Abdallah M. (2020). Determination of antibiotics susceptibility profile of *Shigella* species isolated from children with acute diarrhea. *International Journal of Clinical Microbiology and Biochemical Technology*. 3. <https://doi.org/10.29328/journal.ijcmbt.1001017>.

Alipour M., Talebjannat M., and Nabiuni M. (2012). Polymerase Chain Reaction method for the rapid detection of virulent *Shigella* spp. *International J Molecular Clinical Micro*. 2(1): 134 -137.

AL-Musawi , H.S., AL-Hindi , Z. Sh. And AL-Dulaimy , T.H. (2016). Etiology of Bacterial and Parasitic Enteropathogens among Patients with Acute Diarrhea in Babylon Province . *Iraqi Journal of Biotechnology*,; 15(3): 1-7

Anandan S., Muthuirulandi Sethuvel D. P., Gajendiren R., Verghese V. P., Walia K., and Veeraraghavan B. (2017). Molecular characterization of antimicrobial resistance in clinical *Shigella* isolates during 2014 and 2015: Trends in South India. *Germes*, 7(3):115–122.

Ashkenazi S., Levy I., Kazaronovski V., and Samra Z. (2003). Growing antimicrobial resistance of *Shigella* isolates. *J Antimicrob Chemother*. 51(2):427-436.

Brander R. L., Walson J. L., John-Stewart G. C., Naulikha J. M., Ndonye J., Kipkemoi N., Rwigy D., Singa B. O., and Pavlinac P. B. (2017). Correlates of multi-drug non-susceptibility in enteric bacteria isolated from Kenyan children with acute diarrhea. *PLoS Neglected Tropical Diseases*, 11(10): e005974

- Chhanda M. S., Parvez I., Rumi N. A., Hosen M. H. A., and Islam M. R. (2019). Identification of pathogenic bacteria from infected Thai koi (*Anabas testudineus*). *Asian Journal of Medical and Biological Research*. 5(1):56–62.
- Chung The H., Rabaa M. A., Pham Thanh D., De Lappe N., Cormican M., Valcanis M., Howden B. P., Wangchuk S., Bodhidatta L., Mason C. J., Nguyen Thi Nguyen T., Vu Thuy D., Thompson C. N., Phu Huong Lan N., Voong Vinh P., Ha Thanh T., Turner P., Sar P., Thwaites G., Baker S. (2016). South Asia as a reservoir for the global spread of ciprofloxacin-resistant *Shigella sonnei*: A cross-sectional Study. *PLoS Medicine*. 13(8), e1002055.
- Clinical and Laboratory Standards Institute. (2022). Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI. Supplement. M100, USA.
- Dekker J. P., and Frank K. M. (2015). *Salmonella*, *Shigella*, and *Yersinia*. *Clinics in Laboratory Medicine*. 35(2):225–246.
- Drprabhurajeshwar C, Oli A., Chavan, D., and Kelmani C. (2015). Prevalence and antibiotic susceptibility pattern of fluoroquinolone resistant *Shigella* species isolated from infants' stool in Gulbarga district, Karnataka, India. *Asian Pacific Journal of Tropical Disease*. 5: S116–S120.
- DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. *J Infect Dis*. 1989 Jun;159(6):1126-8. doi: 10.1093/infdis/159.6.1126. PMID: 2656880.
- Halimeh F. B., Rafei R., Diene S., Mikhael M., Mallat H., Achkar M., Dabboussi F., Hamze M., and Rolain, J. M. (2020). Challenges in identification of enteroinvasive *Escherichia coli* and *Shigella* spp. In Lebanon. *Acta Microbiologica Et Immunologica Hungarica*. 67(2):100–106.
- Holt K. E., Baker S., Weill F. X., Holmes E. C., Kitchen A., and Yu J. (2012). *Shigella sonnei* genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe. *Nat. Genet*. 44:1056–1059.
- Hosseini Nave H., Mansouri S., Sadeghi A., and Moradi M. (2016). Molecular diagnosis and anti-microbial resistance patterns among *Shigella* spp. isolated from patients with diarrhea. *Gastroenterology and Hepatology from Bed to Bench*. 9(3): 205–210.
- Ibraheem M. F. (2016). Etiology and clinical manifestations of infectious bloody diarrhea in children Welfare Teaching Hospital." *Iraqi Academic Scientific Journal*. 15(1): 35-39.
- Jain P. A., Kulkarni R. D., Dutta S., Ganavali A. S., Kalabhavi A. S., Shetty P. C., Shubhada C., Hosamani M. A., Appannanavar S. B., and Hanamaraddi D. R. (2020). Prevalence and antimicrobial profile of *Shigella* isolates in a tertiary care hospital of North Karnataka: A 12-year study. *Indian Journal of Medical Microbiology*. 38(1):101–108.
- Jain P. A., Kulkarni R. D., Dutta S., Ganavali A. S., Kalabhavi A. S., Shetty P. C., Shubhada C., Hosamani M. A., Appannanavar S. B., and Hanamaraddi D. R. (2020). Prevalence and antimicrobial profile of *Shigella* isolates in a tertiary care hospital of North Karnataka: A 12-year study. *Indian Journal of Medical Microbiology*. 38(1):101–108.
- Jomezadeh N., Babamoradi S., Kalantar E., and Javaherizadeh H. (2014). Isolation

- and antibiotic susceptibility of *Shigella* species from stool samples among hospitalized children in Abadan, Iran. *Gastroenterology and Hepatology from Bed to Bench*. 7(4):218–223.
- Kahsay A. G., and Muthupandian S. (2016). A review on sero diversity and antimicrobial resistance patterns of *Shigella* species in Africa, Asia and South America, 2001–2014. *BMC Res Notes*. 9 (1):422.
- Koneman E. W., Allen S. D., Janda W. M., Schreckenberger P. C., and Winn, W. C. (1997). *Diagnostic microbiology. The nonfermentative Gram-negative bacilli*. Philadelphia: Lippincott-Raven Publishers. 5(4): 253-320.
- Lampel K. A., and Maurelli A.T. (2007) *Shigella* species. Ch 15 In: Doyle MP, Beuchat LR (eds) *Food microbiology: Fundamentals and frontiers*. 3rd ed, ASM Press, Washington D.C., p. 323–341.
- MacFaddin, J.F. (2000). *Biochemical tests for identification of medical bacteria* (3rd ed.), Lippincott Williams and Wilkins, USA.
- Maharjan S., Rayamajhee B., Shrestha A., and Acharya J. (2017). Serotyping and antibiotic susceptibility patterns of *Vibrio* and *Shigella* isolates from diarrheal patients visiting a tropical and infectious diseases hospital in central Nepal. *BMC Research Notes*. 10(1): 626.
- Nataro J. P., Bopp C. A., Fields P. I., Kaper J. B., and Strockbine, N. A. (2007). *Escherichia, Shigella and Salmonella*. *Manual of Clinical Microbiology*.
- Ngoshe I., Denué B., Bello H., Akawu C., and Gashau W. (2017). Prevalence and antimicrobial susceptibility of *Shigella* species isolates from diarrheal stool of patients in a tertiary health facility in northeastern Nigeria. *Sub-Saharan African Journal of Medicine*. 4(4): 96 - 104.
- Niyogi S. K. (2005). *Shigellosis*. *Microbiol*. 43:133–143.
- Nygren B. L., Schilling K. A., Blanton E. M., Silk B. J., Cole D. J., and Mintz E. D. (2013). Foodborne outbreaks of shigellosis in the USA, 1998–2008. *Epidemiol Infect*. 141:233–241.
- Pakbin B., Didban A., Khazaei Monfared Y., Mahmoudi R., Peymani, A., and Modabber M. (2021). Antibiotic susceptibility and genetic relatedness of *Shigella* species isolated from food and human stool samples in Qazvin, Iran. *BMC Research Notes*. 14:144-120.
- Pollock H. M., and Dahlgren B. J. (1974). Clinical evaluation of enteric media in the primary isolation of *Salmonella* and *Shigella*. *Applied Microbiology*. 27(1):197–201.
- Rahman M., and Sarker P. (2021). Antibiotic resistance studies of *Escherichia coli* and *Salmonella* species isolated from diarrheal patients. *African Journal of Biological Sciences*. 3(3):122-130.
- Ranjbar R., Ali K., Shohreh F., Giovanni M G., and Caterina M. (2014). Typing methods used in the molecular epidemiology of microbial pathogens: a how-to guide. *New Microbiol*. 37(1):1-15.
- Saima A. S., Ferhat Abbas R., Rizwan M., Yousaf M., Hassan Y., Naeem M., and Saifullah, S. (2018). Isolation and identification of *Shigella* species from food and water samples of Quetta, Pakistan. *Pure and Applied Biology (PAB)*. 7(1):227-235.
- Sambe-Ba B., Seck A., Wane A. A., Fall-Niang N. K., and Gassama-Sow A. (2013). Sensitivity to antibiotics and

genetic support to resistance of *Shigella flexneri* strains isolated in Dakar from 2001 to 2010]. *Bull Soc Pathol Exot.* 106(2):89–94.

Sati H. F., Bruinsma N., Galas M., Hsieh J., Sanhueza A., Ramon Pardo P., and Espinal M.A. (2019). Characterizing *Shigella* species distribution and antimicrobial susceptibility to ciprofloxacin and nalidixic acid in Latin America between 2000–2015. *PLoS ONE.* 14: e0220445.

Sheikh A. F., Moosavian M., Abdi M., Heidary M., Shahi F., Jomehzadeh N., Mohammadi S. S., Saki M., and Khoshnood S. (2019). Prevalence and antimicrobial resistance of *Shigella* species isolated from diarrheal patients in Ahvaz, southwest Iran. *Infect. Drug Resist.* 12:249-253.